IL6 secreted by Ewing sarcoma tumor microenvironment confers anti-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Lissat, Andrej ^a   Joerschke, Mandy ^b   Shinde, Dheeraj A ^c   Braunschweig, Till ^d   Meier, Angelina ^b   Makowska, Anna ^f   Bortnick, Rachel ^b   Henneke, Philipp ^b   Herget, Georg ^b   Gorr, Thomas A ^b,e   Kontny, Udo ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f UNIVERSITY OF AACHEN MEDICAL CENTER   (Germany)

Author keywords

Apoptosis; Ewing sarcoma; IL6; Migration; Tumor microenvironment

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PROPIDIUM IODIDE; STAT3 PROTEIN; IL6 PROTEIN, HUMAN; IL6R PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL FATE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG RESISTANCE; EWING SARCOMA; EWING SARCOMA CELL LINE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LIMIT OF DETECTION; METASTASIS POTENTIAL; MTT ASSAY; PARACRINE SIGNALING; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; BONE TUMOR; CELL MOTION; CELL SURVIVAL; DISEASE COURSE; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; PARACRINE COMMUNICATION; PHOSPHORYLATION; RECEPTORS, INTERLEUKIN-6; SARCOMA, EWING; STAT3 TRANSCRIPTION FACTOR; TUMOR MICROENVIRONMENT;

EID: 84937826740     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1564-7     Document Type: Article

References (42)

1. Dirksen U, Jurgens H. Approaching Ewing sarcoma. Future Oncol. 2010;6:1155-62.
2. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012;30:4148-54.
3. Lissat A, Chao MM, Kontny U. Targeted therapy in Ewing sarcoma. ISRN Oncol. 2012;609439.
4. Subbiah V, Kurzrock R. Ewing's sarcoma: overcoming the therapeutic plateau. Discov Med. 2012;13:405-15.
5. Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, et al. A molecular function map of Ewing's sarcoma. PLoS One. 2009;4, e5415.
6. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-99.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
8. Durbin M, Randall RL, James M, Sudilovsky D, Zoger S. Ewing's sarcoma masquerading as osteomyelitis. Clin Orthop Relat Res. 1998;176-185.
9. Bacci G, Balladelli A, Forni C, Longhi A, Serra M, Fabbri N, et al. Ewing's sarcoma family tumours. Differences in clinicopathological characteristics at presentation between localised and metastatic tumours. J Bone Joint Surg Br. 2007;89:1229-33.
10. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol. 2003;84:151-9.
11. Nagel S, Scherr M, Quentmeier H, Kaufmann M, Zaborski M, Drexler HG, et al. HLXB9 activates IL-6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3. Leukemia. 2005;19:841-6.
12. Egler RA, Burlingame SM, Nuchtern JG, Russell HV. Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clin Cancer Res. 2008;14:7028-34.
13. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997;89:227-34.
14. Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 2009;69:329-37.
15. Pu YS, Hour TC, Chuang SE, Cheng AL, Lai MK, Kuo ML. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate. 2004;60:120-9.
16. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103-13.
17. Wegiel B, Bjartell A, Culig Z, Persson JL. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer. 2008;122:1521-9.
18. Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, et al. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene. 2007;26:2822-32.
19. Liu Q, Li G, Li R, Shen J, He Q, Deng L, et al. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol. 2010;100:165-76.
20. Tang CH, Chen CF, Chen WM, Fong YC. IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells. J Biol Chem. 2011;286:11056-66.
21. De Luca A, Lamura L, Gallo M, Maffia V, Normanno N. Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J Cell Biochem. 2012;113:3363-70.
22. Touboul C, Lis R, Al Farsi H, Raynaud CM, Warfa M, Althawadi H, et al. Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model. J Transl Med. 2013;11:28.
23. Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46:1223-31.
24. Mitsuyama K, Sata M, Rose-John S. Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine Growth Factor Rev. 2006;17:451-61.
25. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL6 alpha-receptor/IL6ST complex. Science. 2003;300:2101-4.
26. Weidle UH, Klostermann S, Eggle D, Kruger A. Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer. Cancer Genomics Proteomics. 2010;7:287-302.
27. Werner S, Mendoza A, Hilger RA, Erlacher M, Reichardt W, Lissat A, et al. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma. Cancer Chemother Pharmacol. 2008;62:19-31.
28. Jung HC, Eckmann L, Yang SK, Panja A, Fierer J, Morzycka-Wroblewska E, et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest. 1995;95:55-65.
29. Inoue K, Sugiyama H, Ogawa H, Yamagami T, Azuma T, Oka Y, et al. Expression of the interleukin-6 (IL-6), IL-6 receptor, and gp130 genes in acute leukemia. Blood. 1994;84:2672-80.
30. Karlovich C, Duchateau-Nguyen G, Johnson A, McLoughlin P, Navarro M, Fleurbaey C, et al. A longitudinal study of gene expression in healthy individuals. BMC Med Genomics. 2009;2:33.
31. Olk-Batz C, Poetsch AR, Noellke P, Claus R, Zucknick M, Sandrock I, et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood. 2011;117:4871-80.
32. Lissat A, Vraetz T, Tsokos M, Klein R, Braun M, Koutelia N, et al. Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am J Pathol. 2007;170:1917-30.
33. Kontny U, Hammerle K, Klein R, Shayan P, Mackall CL, Niemeyer CM. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis. Cell Death Differ. 2001;8:506-14.
34. Deryugina, EI and Quigley, JP. Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem Cell Biol. 2008; 130:1119-30.
35. David E, Tirode F, Baud'huin M, Guihard P, Laud K, Delattre O, et al. Oncostatin M is a growth factor for Ewing sarcoma. Am J Pathol. 2012;181:1782-95.
36. Cheng YC, Liang CM, Chen YP, Tsai IH, Kuo CC, Liang SM. F-spondin plays a critical role in murine neuroblastoma survival by maintaining IL-6 expression. J Neurochem. 2009;110:947-55.
37. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007;117:3988-4002.
38. Saidi A, Hagedorn M, Allain N, Verpelli C, Sala C, Bello L, et al. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer. 2009;125:1054-64.
39. Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M, Takeyama H. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer. 2014;110:469-78.
40. Erez N, Glanz S, Raz Y, Avivi C, Barshack I. Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. Biochem Biophys Res Commun. 2013;437:397-402.
41. Al Rakan MA, Colak D, Hendrayani SF, Al Bakheet A, Al Mohanna FH, Kaya N, et al. Breast stromal fibroblasts from histologically normal surgical margins are pro-carcinogenic. J Pathol. 2013;231:457-65.
42. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243-54.